Cargando…
ADAM10 Plasma and CSF Levels Are Increased in Mild Alzheimer’s Disease
ADAM10 is the main α-secretase that participates in the non-amyloidogenic cleavage of amyloid precursor protein (APP) in neurons, inhibiting the production of β-amyloid peptide (Aβ) in Alzheimer’s disease (AD). Strong recent evidence indicates the importance of the localization of ADAM10 for its act...
Autores principales: | Pereira Vatanabe, Izabela, Peron, Rafaela, Mantellatto Grigoli, Marina, Pelucchi, Silvia, De Cesare, Giulia, Magalhães, Thamires, Manzine, Patricia Regina, Figueredo Balthazar, Marcio Luiz, Di Luca, Monica, Marcello, Elena, Cominetti, Marcia Regina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957802/ https://www.ncbi.nlm.nih.gov/pubmed/33670873 http://dx.doi.org/10.3390/ijms22052416 |
Ejemplares similares
-
Alpha-Secretase ADAM10 Regulation: Insights into Alzheimer’s Disease Treatment
por: Peron, Rafaela, et al.
Publicado: (2018) -
Dysexecutive mild cognitive impairment associated to frontal atrophy:
Case report
por: Balthazar, Marcio Luiz Figueredo, et al.
Publicado: (2008) -
Category verbal fluency performance may be impaired in amnestic mild
cognitive impairment
por: Balthazar, Márcio Luiz Figueredo, et al.
Publicado: (2007) -
Hippocampal atrophy and verbal episodic memory performance in
amnestic mild cognitive impairment and mild Alzheimer’s disease: A preliminary
study
por: Marchiani, Nathalia Carollina Peruzza, et al.
Publicado: (2008) -
ADAM10 plasma levels predict worsening in cognition of older adults: a 3-year follow-up study
por: Oliveira Monteiro, Maria Patrícia A., et al.
Publicado: (2021)